Mutations in the oncoprotein KRAS occur in about 25% of cancer cases and are associated with poor prognosis of the disease. Therefore, scientists believe that blocking KRAS signaling is a potential anti-cancer pathway. However, previous decades of research have shown that this protein may be a “non-medicinal” target because… Continue Reading Nature: KRAS drugs enter the “outbreak period”, 5 products carry out human trials

  On April 3, a study published in the journal Nature, scientists from Stanford University found that blocking the activity of protein CD22 with an antibody can improve cognitive behavior in aging mice. Dr. Tony Wyss-Coray, a professor of neuroscience, led the research. Dr. Wyss-Coray has been working for years… Continue Reading Is it difficult to develop Alzheimer’s disease “new drug”? This target may be a savior